A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy

Trial Profile

A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 13 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top